Key Takeaways GSK's shares have climbed 18.6% on strong Q3 results and increased full-year sales and profit guidance. Specialty Medicines sales are rising, driven by HIV, Respiratory and Oncology growth.U.S. vaccine sales are declining, though GSK sees sales toward the high end of its 2025 guidance range.GSK (GSK) stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, wherein the British drugmaker beat estimates for both earnings and sales. The company ...